High glucose levels increase influenza-associated damage to the pulmonary epithelial-endothelial barrier
Abstract
Diabetes mellitus is a known susceptibility factor for severe influenza virus infections. However, the mechanisms that underlie this susceptibility remain incompletely understood. Here, the effects of high glucose levels on influenza severity were investigated using an in vitro model of the pulmonary epithelial-endothelial barrier as well as an in vivo murine model of type II diabetes. In vitro we show that high glucose conditions prior to IAV infection increased virus-induced barrier damage. This was associated with an increased pro-inflammatory response in endothelial cells and the subsequent damage of the epithelial junctional complex. These results were subsequently validated in vivo. This study provides the first evidence that hyperglycaemia may increase influenza severity by damaging the pulmonary epithelial-endothelial barrier and increasing pulmonary oedema. These data suggest that maintaining long-term glucose control in individuals with diabetes is paramount in reducing the morbidity and mortality associated with influenza virus infections.
Introduction
Every year influenza A virus (IAV) infects 5–15% of the world’s population (Goeijenbier et al., 2017; Stöhr, 2002). Typically, influenza virus causes an acute and self-limiting disease. However, influenza virus can cause severe disease in individuals with certain chronic medical conditions, including diabetes mellitus (Short et al., 2014). Upon infection with influenza virus, patients with diabetes have triple the risk of hospitalisation, quadruple the risk of admission to the intensive care unit and double the risk of a fatal outcome compared to individuals with no underlying illness (Allard et al., 2010; Wilking et al., 2010). However, the mechanisms that drive this susceptibility remain incompletely understood.
Diabetes is characterised by chronically high blood glucose levels (hyperglycaemia) and is separated into two primary categories: type I (T1D) and type II (T2D). T1D accounts for ~10% of cases (Chatterjee et al., 2017) and is generally regarded as an autoimmune disorder in which the immune system attacks the insulin-producing pancreatic β-cells (Brody, 2012; Federation ID, 2015). The remaining ~90% of cases belong to the T2D category which is characterised by relative insulin deficiency as a result of pancreatic β-cell dysfunction and insulin resistance (Chatterjee et al., 2017; Defronzo, 2009). Diabetes is associated with complications that affect multiple organ systems (Abdel-Rahman et al., 2012). Notably, when compared to healthy individuals, people with diabetes have a two- to fourfold increased risk of cardiovascular disease (Rao Kondapally Seshasai et al., 2011). Similarly, elevated blood glucose levels in patients with diabetes are associated with kidney damage and the development of diabetic kidney disease (Carpentier et al., 2018).
In addition to being associated with the micro- and macrovascular complications of diabetes, hyperglycaemia is also associated with the increased susceptibility to infectious diseases (Critchley et al., 2018). For example, in a Danish population, each 1 mmol/L increase in plasma glucose level was associated with a 6% increased risk of hospitalisation for pneumonia (Benfield et al., 2007). In the specific case of IAV, hyperglycaemia may increase disease severity via either; immunosuppression (Reading et al., 1998), increased epithelial infection (Kohio and Adamson, 2013) and/or, altered activity of transporters responsible for keeping the lung free of oedematous fluid (Yamashita et al., 1992; Rivelli et al., 2012).
Thaiss and colleagues recently showed that hyperglycaemia contributes to the elevated severity of enteric infections in patients with diabetes by increasing the permeability of the gut epithelium (Thaiss et al., 2018). Specifically, GLUT2, a bidirectional glucose transporter, was identified as a key driver of dysfunction of the epithelial junctional complex (Thaiss et al., 2018). In addition to their role in the gut, the epithelial junctional complex plays an important role in the lung by limiting the amount of fluid present in the alveolar airspace. Junctional proteins are formed between both pulmonary epithelial cells and pulmonary endothelial cells, although the epithelial cell component plays a more significant role keeping the lung free of fluid (Short et al., 2014). We have previously demonstrated that IAV can damage junctional proteins between adjacent human alveolar epithelial cells and therefore impair efficient gas-exchange (Short et al., 2016). The findings of Thaiss and colleagues (Thaiss et al., 2018) raise the intriguing possibility that IAV-induced damage to epithelial tight junctions is further exacerbated in the context of hyperglycaemia and that this may account for the increased severity of influenza seen in patients with diabetes.
Here, we use an in vitro co-culture model of the pulmonary epithelial-endothelial barrier and a murine model of T2D to provide new insights into the role of hyperglycaemia and IAV-induced barrier damage in the lung. We show that compared to normal glucose concentrations, elevated glucose levels prior to IAV infection increase virus-induced barrier damage, both in vitro and in vivo, and that this damage is associated with endothelial-driven inflammation.
Results
A history of high glucose increases influenza-induced barrier damage in an in vitro epithelial-endothelial co-culture
To determine the role of high glucose levels (representative of hyperglycaemia) in IAV-induced barrier damage, we adapted our previously described model of the human alveolar epithelial-endothelial barrier (Short et al., 2016; Figure 1A). This is a model of the distal lung region where, in vivo, epithelial cells are entirely covered by a fluid layer, known as the alveolar lining fluid, to facilitate efficient gas exchange (Fronius et al., 2012). As such, in the in vitro model of this region the cells are cultured in medium rather than at an air-liquid interface, which is more appropriate for upper airway models. To mimic normal or hyperglycaemic conditions, respectively, the medium of the lower co-culture compartment contained either 7 mM glucose or 12 mM glucose (Figure 1A). These concentrations were selected as these reflect clinically relevant glucose levels (i.e. >7 mM glucose is considered diabetic) (Danaei et al., 2011; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003). Cells differentiated within 3–5 days of culture as previously characterised within this co-culture model (Hermanns et al., 2004). The development of an elevated TEER was not affected by the differing glucose concentrations (Figure 1—figure supplement 1), and culture of primary endothelial cells in RPMI media did not affect their endothelial phenotype (Figure 1—figure supplement 2) as has been previously described (Short et al., 2016). IAV was then added to the upper compartment to mimic IAV infection via the respiratory route. Importantly, infections of all treatment groups were performed in the presence of 12 mM glucose (in both the upper and lower compartment) to mimic the fact that upon physiological stressors, such as IAV infection, individuals typically experience elevated blood glucose levels (Marik and Bellomo, 2013; Karlsson et al., 2019). Barrier integrity was then compared between co-cultures with a history of elevated (12 mM) glucose levels (henceforth referred to as ‘high glucose co-cultures’) and a history of healthy (7 mM) glucose (levels henceforth referred to as ‘low glucose co-cultures’) Strikingly, following IAV infection, high glucose co-cultures had a significantly greater decrease in TEER compared to low glucose co-cultures (Figure 1B). These data were consistent with the increased permeability to FITC-labeled dextran observed in infected high glucose co-cultures relative to infected low glucose co-cultures (Figure 1B).
Previously, it has been suggested that high glucose conditions increase IAV replication in vitro (Kohio and Adamson, 2013). Therefore, the possibility that the observed barrier damage in the high glucose co-cultures was the result of increased viral replication was explored. However, no statistically significant difference in viral messenger RNA (mRNA) or infectious virus in supernatant was observed between the different glucose conditions (Figure 1C).
Human umbilical vein endothelial cells exposed to high glucose concentrations have an increased level of apoptosis compared to cells in lower glucose concentrations (Risso et al., 2001). Therefore, we next investigated whether the observed barrier damage in the infected high glucose co-cultures was the result of increased cell death via the crude measure of lactate dehydrogenase (LDH) release. While LDH levels cannot definitively rule out a role of cell death, no significant difference was observed in cells from the high and low glucose co-cultures (Figure 1D).
Together, these data suggest that a history of high glucose increases the IAV-induced damage to the epithelial-endothelial barrier in vitro in the absence of wide-spread cell death or increased viral replication.
High glucose barrier damage was dependent upon the presence of endothelial cells
To assess if endothelial cells contributed to the observed barrier damage, mono-cultures of epithelial cells were established and subjected to the same experimental protocols as the co-cultures (Figure 2A). Importantly, as epithelial cells constitute the main component of the pulmonary epithelial-endothelial barrier, mono-cultures still displayed an elevated TEER after 4–5 days in culture (data not shown). However, endothelial cells provided a stabilising effect on the integrity of the epithelial barrier (Figure 2—figure supplement 1), with co-cultures having a significantly higher pre-infection TEER when compared to epithelial mono-cultures. Accordingly, mono and co-cultures were not directly compared; rather mono-cultures with 7 mM glucose were compared to mono-cultures with 12 mM glucose. Following IAV infection, infected high glucose mono-cultures showed no statistically significant decrease in TEER overtime compared to infected low glucose mono-cultures (Figure 2B). Similarly, no difference in epithelial permeability to FITC-labelled dextran was observed (Figure 2B). Consistent with these data, no significant difference in viral replication (Figure 2C) nor LDH release was observed (Figure 2D). Thus, given that high glucose IAV-induced barrier damage was not observed in the absence of endothelial cells, these data suggest that endothelial cells are the main drivers of barrier damage observed in this in vitro model.
IAV-induced barrier damage in infected high glucose co-cultures is associated with a pro-inflammatory response in endothelial cells
We next sought to determine how endothelial cells contributed to the barrier damage observed in IAV-infected high glucose co-cultures. To this end, the transcriptome of endothelial cells from high and low glucose co-cultures was assessed using RNASeq. At 24 hr post-IAV infection, numerous differentially expressed genes were identified in endothelial cells derived from infected co-cultures relative to endothelial cells derived from uninfected co-cultures (Figure 3A). Many of these genes were differentially expressed after infection under both low and high glucose conditions (Figure 3B). Strikingly, certain pathways that were enriched in endothelial cells derived from infected, low glucose co-cultures were not enriched in endothelial cells derived from infected, high glucose co-cultures (Figure 3C). Namely, while both low and high glucose endothelial cells expressed pathways associated with ‘defence response to virus’ and ‘immune system processes’, high glucose endothelial cells lacked a concomitant increase in regulatory pathways otherwise seen in low glucose endothelial cells (Figure 3C). These data suggest that endothelial cells derived from infected high glucose co-cultures may be in a more pro-inflammatory state than their counterparts in low glucose conditions. Consistent with this hypothesis, endothelial cells from IAV-infected high glucose co-cultures expressed significantly higher levels of pro-inflammatory chemokine CXCL8 compared to endothelial cells from IAV-infected low glucose co-cultures (Figure 3D). Similarly, we observed an increase in IL-6 and IL-8 protein levels in endothelial supernatant 24 hr post-infection (Figure 3E). To determine whether high glucose endothelial cells, in the presence of IAV, produced a soluble pro-inflammatory factor that damaged the epithelial-endothelial barrier, the basolateral supernatant from high and low glucose co-cultures was harvested. This supernatant was then transferred to uninfected high and low glucose co-cultures. The transfer of the cell culture supernatant from high-glucose, infected co-cultures was sufficient to induce barrier damage in uninfected cells when compared to normal glucose conditions (Figure 3F). Consistent with a heat-labile soluble protein (such as a cytokine) driving the observed phenotype, the transfer of heat-treated supernatant from high glucose conditions did not damage the epithelial-endothelial barrier (Figure 3F). Furthermore, infection using ultraviolet inactivated virus did not induce barrier damage, even under hyperglycaemic conditions, indicating that initially, active virus is required to induce a reduction in TEER (Figure 3—figure supplement 1). These data suggest that the observed TEER decrease is not due to the presence of viral PAMPS/antigen in the media as it has been previously demonstrated that vRNA and mRNA remains present up to 70°C (Jonges et al., 2010). Interestingly, the somewhat slower kinetics of the TEER drop after supernatant transfer indicates a possibility of indirect action of the cytokine(s); that is, cytokines could trigger epithelial cells in the co-culture to produce another cytokine that then in turn damages the barrier. IL-1β is known to increase interstitial epithelial barrier permeability (Al-Sadi and Ma, 2007). We therefore assessed the effect of introducing an IL-1 antagonist to the system. No difference in barrier integrity with and without Anakinra was observed (Figure 3—figure supplement 2), indicating that while the phenotype is likely due to a soluble factor, it is not IL-1 dependent. These results are to be expected due to the redundancy in innate host defence pathways for pathogen recognition (Nish and Medzhitov, 2011).
IAV-induced barrier damage in infected high glucose co-cultures is the result of an impaired epithelial junctional complex
A pro-inflammatory environment is known to facilitate the damage of the junctional complex between adjacent epithelial cells and increase barrier permeability (Short et al., 2014). Similarly, hyperglycaemia can damage the integrity of junctional complex between epithelial cells in the gut (Thaiss et al., 2018). We therefore assessed the integrity of the epithelial junctional complex in infected high and low glucose co-cultures. We elected to focus on the junctional proteins between adjacent epithelial cells, rather than endothelial cells, as the epithelium constitutes more than 90% of resistance to protein transport across the epithelial-endothelial barrier and thus contributes the largest amount to the TEER in the co-culture system (Short et al., 2014). No difference in epithelial E-cadherin staining was observed between low and high glucose co-cultures (Figure 4A). However, infected high glucose co-cultures had significantly lower levels of Claudin-4 and JAM-1 between adjacent epithelial cells compared to infected low glucose co-cultures (Figure 4B & C). Consistent with our hypothesis that a soluble factor is driving the loss of barrier integrity, co-staining of Claudin-4 and the influenza A nucleoprotein demonstrate that barrier damage occurred in both infected and bystander cells (Figure 4D). To confirm that this damage of the junctional complex was dependent on endothelial cells, the same semi-qualitative analysis was performed on epithelial mono-cultures. In contrast to the co-cultures, there was no difference in junctional integrity of IAV-infected epithelial cells in low or high glucose mono-cultures (Figure 5). Taken together, these data suggest that under conditions of high glucose in vitro, active IAV triggers a pro-inflammatory response in endothelial cells which in turn damages the epithelial junctional complex.
High glucose levels in vivo are associated with more severe influenza and loss of tight junction integrity between pulmonary epithelial cells
Our in vitro findings are limited by constraints of the in vitro model, including the fact that only primary endothelial cells (and not primary epithelial cells) were employed. Thus, we next sought to validate our in vitro findings in a more complex in vivo model. To this end, we employed a well-established murine model of T2D where homozygote mice (leprdb/db) are obese and hyperglycaemic whilst their heterozygote (leprdb/+) counterparts are not (Kodama et al., 1994). Hyperglycaemia in leprdb/db mice was confirmed with a blood glucose test prior to infection (Figure 6A). Heterozygote and homozygote mice were subsequently infected with IAV and disease severity was monitored overtime. As demonstrated previously, weight-loss is not a clear marker for IAV disease severity of leptin receptor-deficient mice (Radigan et al., 2014). Consistent with these results, leprdb/db mice showed less weight loss than their leprdb/+ counterparts (data not shown). It is well recognised that pulse-oximetry is a non-invasive measure of lung injury (Lax et al., 2014) that more accurately predicts disease severity than systemic weight loss in the case of murine influenza studies (Verhoeven et al., 2009). Moreover, blood oxygen saturation is a non-invasive measure of barrier damage – as when the epithelial-endothelial barrier is damaged gas exchange will occur less efficiently resulting in lower blood oxygen saturation. IAV-infected leprdb/db mice had significantly lower blood oxygen saturation at three days post-infection compared to leprdb/+ mice (Figure 6B). Consistent with our in vitro data this was not associated with an increase in infectious virus present (Figure 6C); however, there was difference in viral messenger RNA (mRNA) between the homozygote and heterozygote mice (Figure 6D). Strikingly, and also consistent with our in vitro data, infected hyperglycaemic leprdb/db mice had a significant reduction in both JAM-1 and Claudin-4 levels between adjacent pulmonary epithelial cells compared to normoglycaemic leprdb/+ mice (Figure 6E–G). Next, we measured pro-inflammatory cytokines in the lungs of infected normo- and hyperglycaemic mice after with IAV infection (Figure 6H). Consistent with our in vitro findings, IAV-infected leprdb/db mice had higher levels of pulmonary pro-inflammatory cytokines than infected leprdb/+ mice, although this often just fell short of statistical significance (e.g. IP-10, p=0.06). Whilst we cannot offer definitive evidence that these cytokines were endothelial cell derived (as was the case with the in vitro data), these data are consistent with our in vitro data that loss of intact tight junctions in the context of IAV and hyperglycaemia is associated with a pro-inflammatory response.
Discussion
It is well established that diabetes increases the risk of developing severe influenza (Hulme et al., 2017). However, the underlying mechanism for this observation remains to be fully elucidated. Here, we show that elevated glucose levels are associated with endothelial cell inflammation, destruction of the epithelial junctional complex and increased IAV severity. We therefore propose that in patients with hyperglycaemia, IAV triggers a pronounced inflammatory response in pulmonary endothelial cells. Secreted protein components of this inflammatory response (most likely cytokines) then damage the epithelial junctional complex and worsen IAV-induced barrier damage.
Hyperglycaemia has long been implicated in development of the various macro- and micro-vascular complications of diabetes. Similarly, hyperglycaemia has been implicated in the severity of both bacterial and viral infections in the respiratory tract (Hulme et al., 2017). Elevated blood glucose levels can directly increase glucose concentrations in airway secretions (Philips et al., 2003). Exposure of epithelial cells to elevated glucose concentrations then facilitates increased IAV replication by augmenting the assembly and activity of the cellular vacuolar-type H+ ATPase (V-ATPase) (Kohio and Adamson, 2013). Interestingly, in the present study, we observed that hyperglycaemia increased IAV-induced barrier damage in vitro and increased influenza severity in vivo in the absence of increased viral replication (although initial viral replication was required to trigger epithelial barrier damage). This discrepancy may be the result of different disease models, IAV strains and/or time points used between studies. Similarly, IAV strain-dependent differences in pathogenesis, difference in cell culture glucose concentrations and the type of endothelial cell used may account for the inconsistencies between the results presented herein and those of our previous studies (Short et al., 2016).
Interestingly, previous studies have described elevated glucose levels can directly affect the activity of ATPases in epithelial cells (Kohio and Adamson, 2013; Yamashita et al., 1992; Rivelli et al., 2012). This is of interest given that the Na,K-ATPase (located on the basolateral side of pulmonary epithelial cells) has been implicated in the pathogenesis of influenza virus (Peteranderl et al., 2016; van de Sandt et al., 2017). Altering the activity of this pump can not only facilitate pulmonary oedema, but it can also affect the formation of the junctional complex between adjacent epithelial cells (Rajasekaran and Rajasekaran, 2003). Therefore, the role of hyperglycaemia, Na,K-ATPase activity and influenza severity warrants further investigation.
At present, we do not know which protein component(s) secreted by endothelial cells are responsible for the barrier damage observed in vitro after exposure to high glucose. Our observation that barrier damage of infected and bystander cells was dependent on heat-labile factors in the cell culture supernatant, as well as the increased inflammatory response under high glucose conditions, is consistent with a causative role for cytokines in this system. Numerous different cytokines, including TNF-α, CXCL8, TNF-β, IFN-γ and IL-6, have been reported to damage the tight junctions of epithelial cells (van de Sandt et al., 2017; Ohkuni et al., 2011; Shen et al., 2017). Indeed, we have previously demonstrated that a combination TNF-α and IFN-γ can reduce the integrity of the epithelial barrier via inhibition of the Na,K-ATPase (van de Sandt et al., 2017), and it is tempting to speculate that a similar cascade of events may occur under high glucose conditions. The in vitro co-culture model developed herein, whilst reductionist and excluding the role that leukocytes may play in disease development, offers a relatively high-throughput model for future studies to delineate the specific role of different pro-inflammatory mediators in barrier damage. It is possible that blocking one or more of these cytokines could be used as a novel treatment option for influenza positive diabetes patients. However, traditionally such therapeutic approaches have been thwarted by inherent redundancies in cytokine signalling and inflammation, as well as the risk of increased viral shedding in treated patients (Karawita et al., 2019). Rather, our findings would suggest that a more beneficial therapeutic approach would be the administration of pharmacological agents to enhance the integrity of the epithelial junctional complex.
Thaiss and colleagues recently showed that hyperglycaemia, through GLUT2-dependent transcriptional reprogramming of epithelial cells, facilitated intestinal tight junction dysfunction (Thaiss et al., 2018). In the present study, we also observed tight junction dysfunction under high glucose conditions. However, it is important to recognise that in contrast to the work of Thaiss and colleagues, the epithelial cells in the present study were only indirectly exposed to differential glucose levels (i.e. differing glucose concentrations were restricted to the lower chamber of the co-culture). Moreover, unlike the study of Thaiss et al., 2018 the endothelial cells in the present study only differed in their history of glucose exposure, and all in vitro groups were exposed to the same glucose concentration at the time of IAV infection. Therefore, the data presented here are more congruent with the so-called ‘legacy effect’ described in patients with diabetes. The legacy effect has been used to explain the observation that the detrimental effects of elevated glucose levels in patients persist beyond the period of hyperglycaemia (Chen et al., 2016; El-Osta et al., 2008; Miao et al., 2014). Why the legacy effect occurs is unclear but it has been proposed that epigenetic changes (which persist even after transient hyperglycaemia) influence the regulation of NF-κB (Chen et al., 2016; El-Osta et al., 2008; Miao et al., 2014). This could represent a significant challenge to reducing the severity of influenza virus in patients with diabetes, as it would suggest that controlling one’s blood glucose levels for only a limited period of time would not be sufficient to reduce the risk of disease development. Of particular concern are observations that the physiological effects of changes in blood glucose levels can persist for up to 10 years (Holman et al., 2008).
At present, 1 in 11 adults are living with diabetes. Within the next 20 years, this incidence is expected to increase to 1 in 10 adults (Sainsbury et al., 2018). Therefore, given the ever-growing prevalence of diabetes in our society it is imperative that future studies consider the role of diabetes, and more specifically hyperglycaemia, in the pathogenesis of a wide variety of different bacterial and viral pathogens.
Materials and methods
Cell culture
Request a detailed protocolHuman epithelial NCl-H441 cells (which express alveolar type II cell markers [Ren et al., 2016]) were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and cultured in Roswell Park Memorial Institute medium (RPMI) (Gibco, Grand Island, NY) with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO) and 1% penicillin-streptomycin (Lonza, Basel, Switzerland). NC1-H441 cells were used at passages 3–8. Primary human pulmonary microvascular endothelial cells (HPMEC) were obtained from Sciencell (Carlsbad, CA) and cultured in endothelial cell growth medium (Sciencell) in fibronectin coated tissue culture flasks (2 μg/cm2, Sigma). HPMEC cells were used at passages 3–7, as at higher passages these cells can demonstrate senescence (Shen et al., 1995). Madin-Darby canine kidney (MDCK) cells were obtained from ATCC and cultured in Dulbecco modified Eagle medium (Gibco) between passages 20 and 50. All cell lines were maintained in a humidified 37°C incubator with 95% O2 and 5% CO2. Each cell line has no mycoplasma contamination to report.
In vitro co-cultures and mono-cultures
Request a detailed protocolIn vitro co-culture and mono-culture models of the pulmonary epithelial-endothelial barrier were established as described previously (Short et al., 2016), whereby epithelial (NCl-H441) cells were seeded atop a transwell membrane whilst primary human endothelial cells were seeded below the transwell membrane. Once the NCI-H441 cells reached confluency, the media in both upper and lower compartments was refreshed every 12 hr. The medium of the upper compartment was refreshed using RPMI (Gibco) with 5% FBS (Sigma), 1 μM dexamethasone (Sigma) and 7 mM of glucose (Gibco), while the lower compartment was refreshed using RPMI (Gibco) with 5% FBS (Sigma) and either 7 mM glucose for the low glucose group or 12 mM glucose for the high glucose group (Gibco) until a transepithelial/endothelial electrical resistance (TEER) of greater than 800 Ω was observed and the cells were deemed ready for viral infection.
Tube formation assay
Request a detailed protocolEndothelial cells form capillary-like structures in response to angiogenic signals found in conditioned media (DeCicco-Skinner et al., 2014). To confirm endothelial morphology remained unchanged by RPMI media, tube formation assay was performed essentially as described previously (DeCicco-Skinner et al., 2014). In short, HPMECs were cultured for 4 days in either endothelial cell growth medium (Sciencell) or RPMI (Gibco) with 5% FBS (Sigma), 1% penicillin-streptomycin (Lonza) and either 7 mM glucose or 12 mM glucose (Gibco). After 4 days of culture, a Corning Costar TC-treated 96-well plate (Sigma) was coated with Cultrex Basement Membrane Extract, Type 2 (BME) (Sigma). Once BME set, cells were seeded at a density of 1.5 × 103 cells/mL in respective media. Tubes formed within 2–4 hr and were imaged using an Eclipse Ts2 inverted microscope (Nikon Instruments, Amsterdam, North Holland, the Netherlands).
Viral strains and titrations
Request a detailed protocolInfluenza virus strain A/Solomon Islands/03/2006 (Solomon Islands/06; H1N1) was used to model IAV infection in vitro. A/Auckland/4/2009 (Auckland/09; H1N1) was used to model IAV infection in vivo. Virus stocks were prepared in embryonated chicken eggs as previously described (Brauer and Chen, 2015). Titres of IAV were determined by plaque assays on MDCK cells, as previously described (Short et al., 2011).
In vitro viral infection
Request a detailed protocolOne hour prior to infection, the medium of the transwell plate was refreshed using RPMI (Gibco) with 2% FBS (Sigma) and 12 mM glucose (Gibco). Cells were infected or mock infected by adding A/Solomon Islands/03/2006 (Solomon Islands/06; H1N1) at multiplicity of infection (MOI) of 0.5 or phosphate buffered saline (PBS) (Gibco) respectively to the upper compartment of the transwell system. Virus was not removed after infection and cells were monitored for 24 hr post-infection.
In vitro ultra-violet inactivated viral infection
Request a detailed protocolA/Solomon Islands/03/2006 (Solomon Islands/06; H1N1) was irradiated with 4 × 1 J/cm2 using a Stratagene crosslinker (UVC 500 Ultraviolet Crosslinker, 254 nm bulbs, Amersham Biosciences, Freiburg, Germany). The irradiated virus was assessed for viral titre prior to infection of the co-culture. In vitro viral infection was performed as previously described in Materials and methods.
In vitro anakinra treatment
Request a detailed protocolWhere relevant, endothelial cells were treated with Kineret (anakinra) (Swedish Orphan Biovitrum, Stockholm, Sweden), an IL-1 receptor antagonist. Specifically, 1 hr prior to influenza virus infection, 10 µg/mL Anakinra was added to the lower compartment of the transwell system.
Transepithelial/endothelial Electrical Resistance (TEER)
Request a detailed protocolThe TEER of the transwell cultures was monitored using an EVOM2 voltohmmeter (World Precision Instruments, Sarasota, FL, USA) with an STX2 chopstick electrode.
Transfer assay
Request a detailed protocolThe in vitro transfer of supernatant from co-cultures was performed as described previously (Delorme-Axford et al., 2013). Cell culture supernatant from endothelial cells grown in co-culture was harvested 24 hr after mock or IAV infection. Harvested media was either heat inactivated for 45 min at 65°C to denature proteins or transferred without heat inactivation. Co-cultures were exposed to harvested media for 24 hr and TEER was monitored during this time.
Lactate dehydrogenase (LDH) release
Request a detailed protocolLDH release was determined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Mannheim, Germany) as per the manufacturer’s guidelines.
FITC-dextran transport assay
Request a detailed protocolPermeability to fluorescein isothiocyanate (FITC)-dextran (Sigma) was measured as described previously (Short et al., 2016).
RNA extraction, cDNA synthesis and quantitative polymerase chain reaction (qPCR)
Request a detailed protocolViral and host RNA was extracted from lysed HPMEC and NCl-H441 samples, cDNA was synthesised, and real time PCR was performed as previously described (Short et al., 2016). Forward and reverse primer sequences for each gene of interest are shown in Table 1. Gene expression was normalised relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression and fold change was calculated using the ΔΔCt method (Schmittgen and Livak, 2008). Viral copy number was determined using IAV strain A/Puerto Rico/8/1934 H1N1 (PR8) virus matrix (M) gene cloned into pHW2000 plasmid and viral copy number was determined as described previously (Short et al., 2013).
RNASeq
Request a detailed protocolSequencing quality was first assessed using FastQC to ensure that all samples had high-quality sequencing data. Reads were then aligned to Hg38 with HISAT2. Read counts were generated using HTSeq count with gencode v24 as the reference gene set. Differential gene expression was determined using EdgeR with a generalised linear model design, and an expression cut-off of two counts per million. Gene Ontology (GO) was analysed with Panther Protein Classification System to identify biological processes that were significantly enriched relative to the entire human genome.
Mouse strains
Request a detailed protocolFemale and male heterozygote and homozygote leprdb on C57BL/6 background were kindly provided by Associate Professor Sumaira Hasnain (Mater Research Institute, Australia). Mice between the ages of 6 to 8-week old were used for all experiments. Mice were housed in individually ventilated cages, under alternating 12 hr light/dark periods with access to clean drinking water and pelletised food ad libitum. All animal experiments were approved by the University of Queensland Animal Ethics Committee (permit no. 071/17).
Murine blood glucose measurements
Request a detailed protocolPrior to infection, blood samples were collected via tail prick and blood glucose levels were measured using a SensoCard Plus blood glucose monitor (Point of Care Diagnostics, North Rocks, NSW Australia) with SensoCard test strips (Point of Care Diagnostics).
In vivo viral infection
Request a detailed protocolMice were infected with 5.5 × 103 plaque forming units (PFU) of influenza A/H1N1/Auckland/09 intranasally in 50 μL PBS or mock-infected with PBS under isoflurane-induced anaesthesia using a Stinger Research Anesthetic Gas Machine (Darvall, Arizona). Mice were monitored daily for weight loss and clinical signs of disease. At day 3 post-infection, mice were euthanised by an intraperitoneal injection of a lethal dose of phentobarbitol (270 mg/kg) (Virbac, Millpera, Australia).
Blood oxygen saturation
Request a detailed protocolBlood oxygen saturation was measured at 3 days post-infection using a collar sensor and Mouseox Plus pulse oximeter (Starr, Oakmont, PA).
Histology
Request a detailed protocolAfter euthanasia, murine lungs were inflated by intratracheal administration of PBS (600 μL). The left lobe was then fixed for at least 24 hr in 10% formalin and then transferred to 70% ethanol for processing by the Core Histology Facility, Translational Research Institute. Samples were imbedded in paraffin wax and sliced to a thickness of 5 μm using a Hyrax M25 Rotary Microtome (Leica Biosystems, Nussloch, Germany).
Immunofluorescence
Request a detailed protocolCells grown on a transwell membrane were fixed, stained and mounted on a glass slide with mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) as previously described (Short et al., 2016). Primary antibodies used were α-E-cadherin (Bioss Company, Beijing, China), α-junctional adhesion molecule 1 (Santa Cruz Biotechnology, Santa Cruz, CA), α-claudin-4 (Life Technologies, Gaithersburg, MD) and a monoclonal antibody (clone HB65 IgG2a) directed against the nucleoprotein of influenza A virus (American Type Culture Collection, Manassas, VA). Secondary antibodies were Alexa 488 α-mouse IgG2a, Alexa 647 α-mouse IgG2a and Alexa 488 α-rabbit IgG (Life Technologies).
Unstained murine lung paraffin sections were de-waxed and rehydrated by a series of xylene and ethanol washes. Slides were then incubated in proteinase K (2 mg/mL) for 10 min at 37°C and subject to a series of PBS and PBS/0.01% Tween-20. Slides were incubated with the relevant primary antibody for 1 hr at room temperature followed by PBS washes. Slides were next treated with 0.01% Trypan blue (Sigma) for 3 min at room temperature. Slides were then incubated for 1 hr at room temperature using the relevant secondary antibody. Sections were subsequently washed with PBS and mounted with mounting medium containing DAPI (Vector Laboratories). All antibodies were diluted in PBS/1% bovine serum albumin (Sigma).
Immunolabelling of transwell membranes and murine lung histological sections were visualised using a Laser Scanning Microscope 710 (LSM 710) (Zeiss, Jena, Germany). Staining intensity of tight junction proteins was quantified using ImageJ software (National Institutes of Health, Bethesda, MD). Specifically, an imageJ macro was created to measure the mean grey value within a 6 cm2 area. Each measurement was taken of an image section with 8–12 nuclei sitting within this 6 cm2 area of transwell confocal images. Three measurements were taken per image, and three images were quantified per transwell membrane. Quantification of murine lung tight junction signal intensity was performed using the same methodology.
Cytokine levels
Request a detailed protocolCytokines in the clarified murine lung homogenate, HPMEC and NCl-H441 co-culture supernatant were measured using the LEGENDplex anti-virus response panel according to the manufacturer’s instructions (Biolegend, San Diago, CA). Outliers were identified and excluded using Grubbs’ test.
Statistical analysis
Request a detailed protocolStatistical analyses were performed using Graph Pad Prism software (version 7.02) for Windows (GraphPad Software, La Jolla, CA).
Data availability
RNA sequencing data generated in this study are available on the Gene Expression Omnibus repository with accession number GSE145232 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145232).
-
NCBI Gene Expression OmnibusID GSE145232. High glucose levels increase influenza-associated damage to the pulmonary epithelial-endothelial barrier.
References
-
Therapeutic modalities in diabetic nephropathy: standard and emerging approachesJournal of General Internal Medicine 27:458–468.https://doi.org/10.1007/s11606-011-1912-5
-
IL-1beta causes an increase in intestinal epithelial tight junction permeabilityThe Journal of Immunology 178:4641–4649.https://doi.org/10.4049/jimmunol.178.7.4641
-
Diabetes and the severity of pandemic influenza A (H1N1) infectionDiabetes Care 33:1491–1493.https://doi.org/10.2337/dc09-2215
-
Influenza virus propagation in embryonated chicken eggsJournal of Visualized Experiments 97:52421.https://doi.org/10.3791/52421
-
Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in type 1 diabetic patientsNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 6:39372.https://doi.org/10.1038/srep39372
-
Endothelial cell tube formation assay for the in vitro study of angiogenesisJournal of Visualized Experiments 91:e51312.https://doi.org/10.3791/51312
-
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemiaJournal of Experimental Medicine 205:2409–2417.https://doi.org/10.1084/jem.20081188
-
Why do we have to move fluid to be able to breathe?Frontiers in Physiology 3:146.https://doi.org/10.3389/fphys.2012.00146
-
10-year follow-up of intensive glucose control in type 2 diabetesNew England Journal of Medicine 359:1577–1589.https://doi.org/10.1056/NEJMoa0806470
-
Influenza virus and glycemic variability in diabetes: a killer combination?Frontiers in Microbiology 8:861.https://doi.org/10.3389/fmicb.2017.00861
-
Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profilingJournal of Clinical Microbiology 48:928–940.https://doi.org/10.1128/JCM.02045-09
-
A delicate balancing act: immunity and immunopathology in human H7N9 influenza virus infectionsCurrent Opinion in Infectious Diseases 32:191–195.https://doi.org/10.1097/QCO.0000000000000538
-
BookChapter 10 - Influence of obesity on the response to influenza infection and vaccinationIn: Johnston RA, Suratt BT, editors. Mechanisms and Manifestations of Obesity in Lung Disease. Academic Press. pp. 227–259.
-
Using a non-invasive assessment of lung injury in a murine model of acute lung injuryBMJ Open Respiratory Research 1:e000014.https://doi.org/10.1136/bmjresp-2013-000014
-
Poly(I:c) reduces expression of JAM-A and induces secretion of IL-8 and TNF-α via distinct NF-κB pathways in human nasal epithelial cellsToxicology and Applied Pharmacology 250:29–38.https://doi.org/10.1016/j.taap.2010.09.023
-
Macrophage-epithelial paracrine crosstalk inhibits lung edema clearance during influenza infectionJournal of Clinical Investigation 126:1566–1580.https://doi.org/10.1172/JCI83931
-
Factors determining the appearance of glucose in upper and lower respiratory tract secretionsIntensive Care Medicine 29:2204–2210.https://doi.org/10.1007/s00134-003-1961-2
-
Role of Na-K-ATPase in the assembly of tight junctionsAmerican Journal of Physiology-Renal Physiology 285:F388–F396.https://doi.org/10.1152/ajprenal.00439.2002
-
Diabetes mellitus, fasting glucose, and risk of cause-specific deathThe New England Journal of Medicine 364:829–841.https://doi.org/10.1056/NEJMoa1008862
-
Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in cultureAmerican Journal of Physiology-Endocrinology and Metabolism 281:E924–E930.https://doi.org/10.1152/ajpendo.2001.281.5.E924
-
High glucose levels induce inhibition of Na,K-ATPase via stimulation of Aldose Reductase, formation of microtubules and formation of an acetylated tubulin/Na,K-ATPase complexThe International Journal of Biochemistry & Cell Biology 44:1203–1213.https://doi.org/10.1016/j.biocel.2012.04.011
-
BookBurden of Disease for Diabetes in Australia: It's Time for More ActionSydney: University of Sydney Press.
-
Analyzing real-time PCR data by the comparative C(T) methodNature Protocols 3:1101–1108.https://doi.org/10.1038/nprot.2008.73
-
Expression of adhesion molecules in cultured human pulmonary microvascular endothelial cellsMicrovascular Research 50:360–372.https://doi.org/10.1006/mvre.1995.1064
-
miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitroAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 312:G123–G132.https://doi.org/10.1152/ajpgi.00316.2016
-
Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant MiceJournal of Visualized Experiments 50:2357.https://doi.org/10.3791/2357
-
Influenza-Induced Inflammation Drives Pneumococcal Otitis MediaInfection and Immunity 81:645–652.https://doi.org/10.1128/IAI.01278-12
-
Pathogenesis of influenza-induced acute respiratory distress syndromeThe Lancet Infectious Diseases 14:57–69.https://doi.org/10.1016/S1473-3099(13)70286-X
-
Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctionsEuropean Respiratory Journal 47:954–966.https://doi.org/10.1183/13993003.01282-2015
-
Influenza—WHO caresThe Lancet Infectious Diseases 2:517.https://doi.org/10.1016/S1473-3099(02)00366-3
-
Human CD8+ T cells damage noninfected epithelial cells during influenza virus infection in vitroAmerican Journal of Respiratory Cell and Molecular Biology 57:536–546.https://doi.org/10.1165/rcmb.2016-0377OC
-
Mortality of 2009 pandemic influenza A(H1N1) in GermanyEurosurveillance 15:19741.https://doi.org/10.2807/ese.15.49.19741-en
Article and author information
Author details
Funding
National Health and Medical Research Council (APP1159959)
- Linda A Gallo
- Kirsty R Short
National Health and Medical Research Council (Early-Career Research Fellowship)
- Linda A Gallo
National Health and Medical Research Council (APP1130815)
- Kyle R Upton
Australian Research Council (DE180100512)
- Kirsty R Short
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
This work was supported by a NHMRC Project grant (APP1159959). LAG is supported by an Early Career Fellowship from the National Health and Medical Research Council and Heart Foundation (Australia). KRU is supported by a NHMRC Career Development Fellowship (APP1130815). KRS is supported by an Australian Research Council DECRA (DE180100512). Kineret (anakinra) was kindly provided by Professor Kate Schroder.
Ethics
Animal experimentation: All animal experiments were approved by the University of Queensland Animal Ethics Committee. (permit no. 071/17).
Copyright
© 2020, Hulme et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,072
- views
-
- 253
- downloads
-
- 22
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Computational and Systems Biology
- Immunology and Inflammation
Diverse antibody repertoires spanning multiple lymphoid organs (i.e., bone marrow, spleen, lymph nodes) form the foundation of protective humoral immunity. Changes in their composition across lymphoid organs are a consequence of B-cell selection and migration events leading to a highly dynamic and unique physiological landscape of antibody repertoires upon antigenic challenge (e.g., vaccination). However, to what extent B cells encoding identical or similar antibody sequences (clones) are distributed across multiple lymphoid organs and how this is shaped by the strength of a humoral response remains largely unexplored. Here, we performed an in-depth systems analysis of antibody repertoires across multiple distinct lymphoid organs of immunized mice and discovered that organ-specific antibody repertoire features (i.e., germline V-gene usage and clonal expansion profiles) equilibrated upon a strong humoral response (multiple immunizations and high serum titers). This resulted in a surprisingly high degree of repertoire consolidation, characterized by highly connected and overlapping B-cell clones across multiple lymphoid organs. Finally, we revealed distinct physiological axes indicating clonal migrations and showed that antibody repertoire consolidation directly correlated with antigen specificity. Our study uncovered how a strong humoral response resulted in a more uniform but redundant physiological landscape of antibody repertoires, indicating that increases in antibody serum titers were a result of synergistic contributions from antigen-specific B-cell clones distributed across multiple lymphoid organs. Our findings provide valuable insights for the assessment and design of vaccine strategies.
-
- Immunology and Inflammation
Adipose tissue inflammation is now considered to be a key process underlying metabolic diseases in obese individuals. However, it remains unclear how adipose inflammation is initiated and maintained or the mechanism by which inflammation develops. We found that microRNA-802 (Mir802) expression in adipose tissue is progressively increased with the development of dietary obesity in obese mice and humans. The increasing trend of Mir802 preceded the accumulation of macrophages. Adipose tissue-specific knockout of Mir802 lowered macrophage infiltration and ameliorated systemic insulin resistance. Conversely, the specific overexpression of Mir802 in adipose tissue aggravated adipose inflammation in mice fed a high-fat diet. Mechanistically, Mir802 activates noncanonical and canonical NF-κB pathways by targeting its negative regulator, TRAF3. Next, NF-κB orchestrated the expression of chemokines and SREBP1, leading to strong recruitment and M1-like polarization of macrophages. Our findings indicate that Mir802 endows adipose tissue with the ability to recruit and polarize macrophages, which underscores Mir802 as an innovative and attractive candidate for miRNA-based immune therapy for adipose inflammation.